Gandjour A - Search Results

1

Nephron overload as a therapeutic target to maximize kidney lifespan.

Luyckx VA, Rule AD, Tuttle KR, Delanaye P, Liapis H, Gandjour A, Romagnani P, Anders HJ. Luyckx VA, et al. Among authors: gandjour a. Nat Rev Nephrol. 2022 Mar;18(3):171-183. doi: 10.1038/s41581-021-00510-7. Epub 2021 Dec 8. Nat Rev Nephrol. 2022. PMID: 34880459 Review.

2

A simulation model to estimate cost-offsets for a disease-management program for chronic kidney disease.

Gandjour A, Tschulena U, Steppan S, Gatti E. Gandjour A, et al. Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):341-7. doi: 10.1586/14737167.2015.972375. Epub 2014 Nov 29. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25434825

3

Costs of patients with chronic kidney disease in Germany.

Gandjour A, Armsen W, Wehmeyer W, Multmeier J, Tschulena U. Gandjour A, et al. PLoS One. 2020 Apr 24;15(4):e0231375. doi: 10.1371/journal.pone.0231375. eCollection 2020. PLoS One. 2020. PMID: 32330140 Free PMC article.

4

Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease.

Adarkwah CC, Gandjour A. Adarkwah CC, et al. Among authors: gandjour a. Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):215-23. doi: 10.1586/erp.11.18. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 21476823

5

Simplifying rules for optimal allocation of preventive care resources.

Gandjour A. Gandjour A. Expert Rev Pharmacoecon Outcomes Res. 2012 Apr;12(2):231-5. doi: 10.1586/erp.12.7. Expert Rev Pharmacoecon Outcomes Res. 2012. PMID: 22458624

6

Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.

Gandjour A. Gandjour A. PLoS One. 2020 Oct 2;15(10):e0236543. doi: 10.1371/journal.pone.0236543. eCollection 2020. PLoS One. 2020. PMID: 33006987 Free PMC article.

7

A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness.

Gandjour A, Stock S. Gandjour A, et al. Health Policy. 2007 Oct;83(2-3):257-67. doi: 10.1016/j.healthpol.2007.01.003. Epub 2007 Mar 1. Health Policy. 2007. PMID: 17335933

8

Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis.

Mueller D, Weyler E, Gandjour A. Mueller D, et al. Among authors: gandjour a. Pharmacoeconomics. 2008;26(6):513-36. doi: 10.2165/00019053-200826060-00005. Pharmacoeconomics. 2008. PMID: 18489201

9

Cost-effectiveness of preventing hip fractures by hip protectors in elderly institutionalized residents in Germany.

Gandjour A, Weyler EJ. Gandjour A, et al. Value Health. 2008 Dec;11(7):1088-95. doi: 10.1111/j.1524-4733.2008.00393.x. Value Health. 2008. PMID: 19602215 Free article.

10

Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.

Mueller D, Gandjour A. Mueller D, et al. Among authors: gandjour a. Value Health. 2009 Nov-Dec;12(8):1106-17. doi: 10.1111/j.1524-4733.2009.00577.x. Epub 2009 Aug 10. Value Health. 2009. PMID: 19706151 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

201 results

Search Page

Filters